Telegraph

7x24 real-time news feed, auto refreshBeijing Time：

All A·Important B·Normal #clinical trial ✕
B
[Maiway Bio: 9MW2821 clinical data will be presented in an oral report at the 2026 ESMO Conference] On October 18, Maiwei Bio (688062.SH) announced that the company will announce the phase II clinical data of the innovative drug 9MW2821 targeting nectin-4 ADC for patients with triple-negative breast cancer (TNBC) in the form of an oral report at the 2026 European Society for Medical Oncology (ESMO) Congress. As of April 10, 2026, among 60 patients with evaluable efficacy, the objective response rate (ORR) was 30.0%, the disease control rate (DCR) was 80.0%, the median progression-free survival (mPFS) was 3.7 months, the median duration of response (mDOR) was 8.7 months, the median overall survival (mOS) has not yet matured, and no new safety signals have been observed. The company is advancing four phase III key registration clinical trials, among which UC single drugs and combination therapies have been included in the national breakthrough therapy list.
#clinical trial#A-share announcement express10-18 15:46
B
[Aidi Pharmaceutical: ADC118 Tablets Received Drug Clinical Trial Approval Notice] On October 15th, Aidi Pharmaceutical (688488.SH) announced that the company and its wholly-owned subsidiaries received the "Drug Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration, agreeing to conduct Phase III clinical trials of ADC118 tablets, a new class 1 drug under development in the field of anti-AIDS. The drug is a triple compound preparation composed of the independently developed HIV integrase strand transfer inhibitor ACC017, emtricitabine, and tenofovir alafenamide, and is intended to be used to treat adults infected with HIV-1.
#clinical trial#A-share announcement express10-15 18:34
B
[Ning Yihua of Jingyu Medical: China’s brain-computer interface DBS has moved from ecological rise to psychiatric breakthrough] October 14th, at the 22nd ICOCS (International Obsessive-Compulsive and Obsessive-Compulsive Spectrum Disorders Society) Annual Meeting held today, Ning Yihua said that brain-computer interface dual-target DBS is the last resort for refractory mental illness. Chinese companies and clinicians have made milestone breakthroughs in the field of treatment of refractory mental illness. A global "first" has been achieved - the brain-computer interface dual-target DBS for opioid addiction has been approved for marketing in China. Jingyu Medical launched two clinical trials of brain-computer interface dual-target DBS in the treatment of refractory obsessive-compulsive disorder in 2016 and 2021. The 6-month complete response rates were both above 75%. Note: Jingyu Medical is an enterprise in the field of brain-computer interfaces for the treatment of addiction and mental diseases. In December 2025, the company's Neurestora® was approved by the China Food and Drug Administration for marketing. It is used for relapse prevention and auxiliary treatment of patients with refractory moderate to severe opioid addiction, becoming the world's first brain-computer interface dual-target DBS system approved for the treatment of drug addiction.
#clinical trial#brain computer interface#interface#medicine10-14 22:15
B
[3 days and 2 boards Laimei Pharmaceutical: Nanocarbon-iron combined radiotherapy is still in phase II clinical trials] On October 14th, Laimei Pharmaceutical (300006.SZ) issued an announcement of abnormal stock trading fluctuations. The company is concerned that the market and media have recently paid attention to the clinical trials of the company’s nanocarbon-iron suspension injection (CNSI-Fe) (referred to as nanocarbon-iron). This matter is mainly due to the company's holding subsidiary Ingrui Medicine recently publishing academic papers on the Phase I clinical trial of its independently developed nanocarbon iron in relevant academic journals, as well as the interpretation of clinical trial results or individual case results disclosed by relevant partner hospitals. As of now, nanocarbon iron combined with radiotherapy is still in the phase II clinical trial stage. Subsequently, the results of the phase II clinical trial of combined radiotherapy must be used to advance the application for breakthrough therapy designation, or conduct phase III clinical trials, apply for drug marketing authorization (NDA) and other core links. There are major uncertainties in the above-mentioned core links, and there are risks such as the results of phase II clinical trials not meeting expectations, the inability to apply for or be approved for breakthrough therapy designation, the inability to conduct or complete phase III clinical trials, the inability to submit or approve NDA, and the delay in review and approval progress.
#clinical trial#A-share announcement express#A-share risk warning announcement10-14 18:29
B
[Bori Pharmaceuticals: BGM0504 tablets received drug clinical trial approval notice] On October 12, Borui Pharmaceuticals (688166.SH) announced that the company's wholly-owned subsidiary Borui Pharmaceuticals recently received the "Drug Clinical Trial Approval Notice" issued by the State Food and Drug Administration, agreeing to conduct clinical trials of BGM0504 tablets in adult patients with type 2 diabetes. BGM0504 is a dual agonist of GLP-1 and GIP receptors independently developed by the company. No similar target in its oral dosage form has been approved for marketing in the world.
#clinical trial#A-share announcement express10-12 20:01
B
[Gan & Lee Pharmaceuticals: The first subject was administered in the Phase I clinical trial of GLR1075 injection] On October 12, Gan & Lee Pharmaceutical (603087.SH) announced that the phase I clinical trial of GLR1075 injection independently developed by the company in China has recently successfully completed the administration of the first subject. This product is a recombinant human albumin preparation, intended for the treatment of hypoalbuminemia in liver cirrhosis and ascites. As of the date of the announcement, only Heyuan Bio's plant-derived recombinant human albumin injection (Aofumin®) has been approved for marketing by the State Food and Drug Administration in China; Tonghua Everett's yeast-derived recombinant human albumin injection has been approved for marketing in Russia and Kyrgyzstan. As of June 30, 2026, the project has invested a total of 81.9161 million yuan in research and development expenses.
#clinical trial#plant#A-share announcement express10-12 16:49
B
[Wantai Bio: Freeze-dried recombinant respiratory syncytial virus vaccine approved for clinical trials] On October 12, Wantai Bio (603392.SH) announced that the company's wholly-owned subsidiary Wantai Canghai received the "Drug Clinical Trial Approval Notice" for the freeze-dried recombinant respiratory syncytial virus vaccine (CHO cells) approved and issued by the State Food and Drug Administration, and agreed to conduct clinical trials to prevent lower respiratory tract diseases caused by RSV infection in people aged 60 and above. The vaccine is an adjuvant-free freeze-dried preparation. Preclinical data shows good safety, but the development and marketing cycle is long and there are uncertainties.
#clinical trial#cell#Virus#vaccine#A-share announcement express10-12 16:01
B
[China Resources Shuanghe: DC7001A capsules have been approved for clinical trials by the U.S. FDA] On October 11, China Resources Shuanghe (600062.SH) announced that the company’s wholly-owned subsidiary Beijing Shuanghe Runchuang Technology received a notice from the U.S. FDA agreeing to conduct clinical trials of DC7001A capsules. The drug is intended to be used to treat systemic lupus erythematosus and has been approved for drug clinical trials by the State Food and Drug Administration.
#clinical trial#A-share announcement express10-11 15:42
B
[Mengke Pharmaceutical: Signed an exclusive license agreement and platform cooperation agreement for MRX-23 with ClearideBio, with a total payment limit of US$750 million] On October 9, Mengke Pharmaceutical (688373.SH) announced that the company plans to sign an exclusive license agreement and platform technology cooperation agreement for the MRX-23 project with ClearideBio of Switzerland. The former involves the global exclusive license of the MRX-23 project; the latter is a multi-project option cooperation based on the company's independently developed new camptothecin-loaded "STOPIN" antibody-conjugated drug platform. ClearideBio can exercise the option for an agreed number of targets or target combination projects as agreed in the agreement. According to the MRX-23 license agreement, an initial payment of US$1 million will be paid as agreed after the agreement comes into effect. This amount is non-refundable after payment; recent development milestone payments are triggered when the licensed product obtains approval of the clinical trial application for the first time. The total nominal maximum payment limit for MRX-23 R&D, registration and sales milestones is US$223 million, and the total maximum payment limit when all platform cooperation projects are exercised and all milestones are achieved is US$750 million.
#clinical trial#EA#A-share announcement express10-09 19:02
B
[Zhongsheng Pharmaceutical: Phase III clinical trial of the first-class innovative drug RAY1225 for weight loss reaches the primary endpoint] On October 8, Zhongsheng Pharmaceutical (002317.SZ) announced that the phase III clinical trial (REBUILDING-2) of the first-class innovative peptide drug RAY1225 injection independently developed by its holding subsidiary Zhongsheng Ruichuang in overweight or obese participants has obtained top-line analysis data and reached the primary endpoint. The results showed that the body weight of the RAY1225 injection 9 mg group was reduced by 22.24% compared with the baseline, and by 20.46% after placebo correction. The weight loss target rate and the improvement of cardiovascular and metabolic indicators were significantly better than the placebo, and the safety was good. The company reminds that the complete results are subject to the final clinical summary report, and there is uncertainty in the drug launch.
#clinical trial#A-share announcement express10-08 18:09
B
[The concept of innovative drugs fluctuated and fell, and Alex dropped by 20cm.] On October 8, the concept of innovative drugs fluctuated and fell by 20cm, with Ellis falling by the limit of 20cm, Bepsis falling by more than 10%, and Yahong Pharmaceutical, Maiwei Biotech, Technomax, Huiyu Pharmaceutical, Rejing Biotech, etc. followed suit. On the news, Arris announced that the phase III clinical trial of fumetinib did not meet the primary study endpoint. Affected by this news, partner ArriVent's US stock price plummeted 47% in a single day on October 6.
#clinical trial#Live broadcast#Innovative drugs#hot landscape creature10-08 09:41
B
[Alice: The phase III clinical trial of fumetinib did not meet the primary study endpoint] On October 7, Ellis (688578.SH) announced that the company's product fumetinib mesylate tablets ("vometinib") monotherapy is FURVENT for the treatment of previously untreated patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations. The Phase III trial did not meet its primary endpoint of progression-free survival (PFS) as assessed by blinded independent central review (BICR). Clinical benefit was observed on secondary endpoints such as investigator-assessed PFS and BICR-assessed confirmed objective response rate (ORR); although overall survival (OS) data are not yet mature, a clear trend of improvement has been observed. The safety profile observed in the FURVENT trial was consistent with previous clinical studies of fumetinib, and no new safety signals were found. Together with ArriVent, the company is evaluating FURVENT's complete data set to determine next steps. As of September 30, 2026, the company has invested a total of approximately 70.82 million yuan in key clinical trials of fumetinib for first-line treatment of exon 20 insertion mutations. The above-mentioned research and development expenses have been included in the profits and losses of the corresponding accounting period when they are incurred, and will not have a significant impact on the company's current performance.
#clinical trial#cell#A-share announcement express10-07 16:28
B
[Betta Pharmaceuticals: BPI-572270 capsules have been approved by the U.S. FDA for clinical trials of new drugs] On October 7, Betta Pharmaceuticals (300558.SZ) announced that the clinical trial application for BPI-572270 capsules submitted by the company's wholly-owned subsidiary Jingyao Biotech was approved by the U.S. FDA and is intended to be used for advanced solid tumors. The drug is a self-developed pan-RAS "non-degradable molecular glue" inhibitor. Preclinical studies have shown that it has a strong inhibitory effect on a variety of RAS mutated tumor cells. The company reminds that the research and development cycle of new drugs is long, the investment is large, and the results of clinical trials and approvals are uncertain, which will not have a significant impact on recent performance.
#clinical trial#molecular#cell#A-share announcement express10-07 16:16
B
[Zhongsheng Pharmaceutical: ZSP1601 tablets are included in the breakthrough therapy drug program] On October 7, Zhongsheng Pharmaceutical (002317.SZ) announced that ZSP1601 tablets, a class of innovative drug independently developed by the company’s holding subsidiary Zhongsheng Ruichuang, was included in the breakthrough therapy drug program by the Drug Evaluation Center of the State Food and Drug Administration, and the proposed indication is metabolism-associated steatohepatitis (MASH). ZSP1601 tablets are a first-in-class innovative drug (First-in-Class) for the treatment of MASH with global independent intellectual property rights and a new mechanism of action. It is a major national new drug creation project. The phase IIb clinical trial of ZSP1601 tablets for the treatment of MASH has obtained positive data results, and the primary efficacy endpoint of pathological improvement was achieved after 48 weeks of treatment. At the same time, it achieves the triple benefits of anti-fibrosis, reducing liver fat content, and improving liver enzymes, with fast onset, robust effect, and excellent safety.
#clinical trial#A-share announcement express10-07 15:49
B
On October 6th, U.S. stock Vaxcyte is now up 27%, having risen nearly 60% earlier. It was reported that the company’s pneumococcal vaccine has reached late-stage clinical trial targets.
#clinical trial#vaccine#Global market intelligence#U.S. stock trends10-06 02:59
A
[The three major U.S. stock indexes opened mixed, Vaxcyte rose more than 54%] On October 5, the three major U.S. stock indexes opened mixed, with the Dow Jones falling 0.14%, the S&P 500 rising 0.08%, and the Nasdaq Composite rising 0.15%. Vaxcyte rose more than 54% after the company's pneumococcal vaccine met late-stage clinical trial goals. Critical Metals rose more than 8% after the company received Greenland's approval for its Tanbreez project mining and closure plan. Vistra Energy rose more than 3% as the United States will provide it with a $4 billion loan to increase nuclear power generation. Cryptocurrency concept stocks generally rose, with Circle, Coinbase, and Strategy rising by more than 2%.
#Coinbase#Meta#clinical trial#vaccine#Global market intelligence#U.S. stock trends10-05 21:30
A
[Vaxcyte U.S. stocks surged over 85% before the market opened] On October 5, the U.S. stock price of Vaxcyte surged over 85% before the market opened, after the company’s pneumococcal vaccine reached late-stage clinical trial targets.
#clinical trial#vaccine#Global market intelligence#U.S. stock trends10-05 18:35
B
[Vaxcyte U.S. stocks surged over 61% before the market opened] On October 5, the U.S. stock price of Vaxcyte surged over 61% before the market opened, after the company’s pneumococcal vaccine reached late-stage clinical trial targets.
#clinical trial#vaccine#Global market intelligence#U.S. stock trends10-05 18:26
B
[Vaxcyte U.S. stocks surged more than 25% before the market opened] On October 5, the U.S. stock price of Vaxcyte surged more than 25% before the market opened, after the company’s pneumococcal vaccine reached late-stage clinical trial targets.
#clinical trial#vaccine#Global market intelligence#U.S. stock trends10-05 18:13
B
On September 30th, AbbVie announced that its drug under development, ABBV-295, showed a weight loss effect of up to 9.8% in a phase 1 clinical trial, showing "meaningful weight loss."
#clinical trial#weight loss pills09-30 17:52
B
[Balitianheng: The first subject has been enrolled in the T-Bren phase III clinical trial] On September 29, Baileytianheng (688506.SH) announced that the company's independently developed injectable T-Bren (HER2ADC) has completed the first subject enrollment in the phase III randomized controlled clinical trial comparing BL-M07D1 with physician-selected chemotherapy in patients with HER2-expressing platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. As of now, T-Bren is conducting 20 clinical trials at home and abroad, and two of its indications have been included in the list of breakthrough therapies by the Drug Evaluation Center of the State Food and Drug Administration.
#clinical trial#A-share announcement express09-29 18:54
B
[Lepu Medical: Subsidiary MWN110 injection has been approved for clinical trials by the U.S. FDA] On September 28, Lepu Medical (300003.SZ) announced that the company’s controlled subsidiary Shanghai Minwei Biotech has received a notice from the U.S. FDA agreeing to conduct clinical trials of MWN110 injection. The drug is a monoclonal antibody targeting ActRIIA/B. The applied indication is overweight or obesity. It has global intellectual property rights and has been approved by CDE for clinical trials in July 2026. Non-clinical studies have shown that the drug alone can significantly reduce body fat percentage, weight and increase muscle mass, while combined use with semaglutide can inhibit muscle loss. At present, no similar drugs have been approved for marketing at home or abroad.
#clinical trial#clone#A-share announcement express09-28 18:39
B
[Hisco: Innovative drug HSK42360-Na tablets are included in the Breakthrough Therapy Drug Program] On September 27, Hisco (002653.SZ) announced that the company's innovative drug HSK42360-Na tablets were officially included in the "Breakthrough Therapy List" by the Drug Evaluation Center of the State Food and Drug Administration for the treatment of recurrent or progressive high-grade gliomas with BRAFV600 mutations. The drug is a BRAF paradoxicalbreaker inhibitor independently developed by the company. It has excellent central nervous system penetration. Clinical trials that have been carried out have shown outstanding efficacy and controllable safety. After being included as a breakthrough therapy, it is expected to obtain priority review qualifications during the marketing application stage and accelerate the marketing process.
#clinical trial#Cisco#EA#A-share announcement express09-27 15:51
B
[Chengda Biotech: Signed Recombinant Tetravalent Enterovirus Vaccine Technology Transfer Contract] On September 24, Chengda Biotech (688739.SH) announced that the company signed a "Recombinant Quadrivalent Enterovirus Vaccine Technology Transfer Contract" with Wiltek, and transferred all rights and interests of the recombinant quadrivalent enterovirus vaccine (Hansenula yeast) project. The technology transfer fee is 46 million yuan (tax included), which will be paid in installments based on milestones; sales commissions and sales milestone rewards will be paid based on the sales of the product after it is launched. The subject product is still in the early stages of research and development, and there are uncertainties in subsequent clinical trials, registration approval and commercialization.
#clinical trial#Virus#vaccine#A-share announcement express09-24 17:20
A
[Four-connected Nanhua Bio: Cell therapy-related technologies and products are still in the research and development stage, and no innovative drugs have been launched or entered the clinical trial stage] On September 22, Nanhua Bio (000504.SZ) issued a stock trading risk warning announcement stating that the company's current main business is biomedicine and energy conservation and environmental protection. Among them, the biomedicine segment mainly provides customers with testing and storage services for biological resources such as stem cells and immune cells. It also cooperates with a number of clinical research institutions to provide them with cell preparation, testing and other services that meet clinical research requirements. The company's cell therapy-related technologies and products are still in the research and development stage, and no innovative drugs have been launched or entered the clinical trial stage. The energy-saving and environmental protection segment is mainly engaged in lithium carbonate business, scrap steel renewable resources and supporting processing and sales.
#clinical trial#stem cells#cell#A-share announcement express#A-share risk warning announcement09-22 18:20
B
[Yahong Pharmaceutical: APL-2501 has completed the enrollment of the first subject in the Phase I clinical trial] On September 22, Yahong Pharmaceutical (688176.SH) announced that the company's independently developed APL-2501 has completed the enrollment of the first subject in the Phase I/II clinical trial in patients with advanced solid tumors. The drug is an anti-CLDN6/9 antibody-drug conjugate independently developed by the company based on a topoisomerase inhibitor. It can be used to treat a variety of advanced solid tumors such as ovarian cancer, non-small cell lung cancer, endometrial cancer, and gastric cancer. The research has been approved by the US FDA and the State Food and Drug Administration, and this matter will not have a significant impact on the company's recent performance.
#clinical trial#cell#A-share announcement express09-22 17:43
B
On September 22, Roche’s ENICEPATIDE met the two primary endpoints of its Phase II clinical trial.
#clinical trial09-22 13:07
B
[AI pharmaceutical company Iambic backed by NVIDIA submits U.S. IPO application] "Science and Technology Innovation Board Daily" reported on the 22nd that Iambic Therapeutics, an AI pharmaceutical company backed by NVIDIA and Qatar's sovereign wealth fund, submitted a U.S. initial public offering (IPO) application on Monday local time. Founded in 2019 (formerly known as Entos), Iambic is currently advancing a pipeline of drug candidates developed using its AI platform to treat solid tumors. Its most advanced drug candidate, IAM1363, is in early-stage clinical trials for the treatment of solid tumors such as breast cancer.
#clinical trial#NVIDIA#AI09-22 08:39
B
[Shenlian Bio: The Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria has reached the primary endpoint] On September 20, Shenlian Biotech (688098.SH) announced that the Phase II clinical study of UB-221 injection, a Class 1 biologic drug independently developed by Shizhiyuan, a subsidiary of the company controlled by the company, for the treatment of chronic spontaneous urticaria has reached the primary endpoint and achieved positive top-line results. A total of 145 subjects were included in the study. The HSS7=0 response rates at week 12 in each dose group of UB-221 were 54%, 53% and 43% respectively, which were significantly higher than the 11% in the placebo group. In terms of safety, UB-221 was generally well tolerated, and no serious adverse events related to treatment occurred. The above-mentioned matters are not expected to have a significant impact on the company's performance in the short term, and subsequent procedures such as phase III clinical research and new drug marketing applications need to be completed.
#clinical trial#A-share announcement express09-20 15:32
B
[State Food and Drug Administration: Establishing a market exclusivity period system for children’s drugs, rare disease drugs and other fields to make corporate R&D investments more secure] On September 20, Yang Sheng, deputy director of the State Food and Drug Administration, said at a press conference of the State Council Information Office that the implementation of the drug experimental data protection system will be promoted and a market exclusivity period system for children’s drugs, rare disease drugs and other fields will be established to make corporate R&D investments more secure. Improve the communication and exchange mechanism for early R&D, and strengthen pre-guidance for innovative drugs with new targets and new mechanisms, so that enterprises can avoid detours in R&D. Expand medical devices, transform clinical innovation results into Spring Rain Action, and formulate clinical trial and review guiding principles in cutting-edge fields such as brain-computer interfaces to pave the way for future industries.
#clinical trial#brain computer interface#Rare disease#interface09-20 10:54